Evaluating the impact of COVID-19 on medication adherence and health care utilization among individuals with psychotic disorders who are prescribed long-acting injectables (LAIs) or clozapine: A population-based study in Manitoba, Canada.
Yushi W MacMillan-WangJennifer M HenselChristine LeongRajat JayasEunice ValenciaArianna YorskiKun LiuPublished in: Schizophrenia research (2024)
COVID-19 had no substantial impact on LAI and clozapine discontinuation rates for patients previously adherent. Outpatient care remained stable, with a significant proportion of visits being done virtually at the outset of the pandemic.